Skip to main content

Generic Prevacid Availability

Last updated on Jan 11, 2023.

Prevacid is a brand name of lansoprazole, approved by the FDA in the following formulation(s):

PREVACID (lansoprazole - capsule, delayed rel pellets;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: May 10, 1995
    Strength(s): 15MG (discontinued) [RLD], 30MG [RLD] [AB]

PREVACID (lansoprazole - for suspension, delayed release;oral)

  • Manufacturer: TAKEDA PHARMS NA
    Approval date: May 3, 2001
    Strength(s): 15MG/PACKET (discontinued), 30MG/PACKET (discontinued)

PREVACID (lansoprazole - tablet, orally disintegrating, delayed release;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: August 30, 2002
    Strength(s): 15MG [RLD] [AB], 30MG [RLD] [AB]

Has a generic version of Prevacid been approved?

Yes. The following products are equivalent to Prevacid:

lansoprazole capsule, delayed rel pellets;oral

  • Manufacturer: ALKEM LABS LTD
    Approval date: January 18, 2019
    Strength(s): 30MG [AB]
    Approval date: September 28, 2017
    Strength(s): 30MG [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: October 15, 2010
    Strength(s): 30MG [AB]
  • Manufacturer: HETERO LABS LTD III
    Approval date: May 18, 2020
    Strength(s): 30MG [AB]
  • Manufacturer: INVENTIA
    Approval date: August 30, 2017
    Strength(s): 30MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: November 10, 2009
    Strength(s): 30MG [AB]
  • Manufacturer: NATCO PHARMA LTD
    Approval date: December 18, 2012
    Strength(s): 30MG [AB]
  • Manufacturer: SANDOZ
    Approval date: April 23, 2010
    Strength(s): 30MG [AB]
  • Manufacturer: SUN PHARM
    Approval date: September 13, 2013
    Strength(s): 30MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: November 10, 2009
    Strength(s): 30MG [AB]
  • Manufacturer: WOCKHARDT
    Approval date: September 14, 2012
    Strength(s): 30MG [AB]
  • Manufacturer: XIROMED
    Approval date: July 25, 2016
    Strength(s): 30MG [AB]
  • Manufacturer: ZYDUS HLTHCARE
    Approval date: August 19, 2013
    Strength(s): 30MG [AB]

lansoprazole tablet, orally disintegrating, delayed release;oral

  • Manufacturer: DR REDDYS
    Approval date: February 1, 2021
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: MYLAN
    Approval date: November 28, 2018
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: TEVA PHARMS USA
    Approval date: September 21, 2017
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: ZYDUS PHARMS
    Approval date: November 27, 2018
    Strength(s): 15MG [AB], 30MG [AB]

Note: No generic formulation of the following product is available.

  • lansoprazole - for suspension, delayed release;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevacid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.